RJA
CELL

Raymond James & Associates’s PhenomeX Inc. Common Stock CELL Stock Holding History

Raymond James & Associates’s Portfolio CELL Stock Details CELL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-12,103
Closed -$542K – 4296
2021
Q2 		$542K Buy
12,103
+4,490
+59% +$208K ﹤0.01% 3021
2021
Q1 		$382K Sell
7,613
-1,082
-12% -$73.8K ﹤0.01% 3202
2020
Q4 		$777K Buy
8,695
+625
+8% +$52.6K ﹤0.01% 2506
2020
Q3 		$616K Buy
+8,070
New +$512K ﹤0.01% 2483

Other funds holding CELL

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Raymond James & Associates's CELL Position: Q3 2021 in Review

Raymond James & Associates sold out of PhenomeX Inc. Common Stock (CELL) in Q3 2021, closing a stake of 12,103 shares — an estimated $542K sold.

Raymond James & Associates first reported a position in CELL in Q3 2020 and held it in 4 quarters. The position peaked at $777K in Q4 2020. 137 funds tracked by Wall St. Rank hold CELL as of Q3 2021.

  • Raymond James & Associates reported no remaining PhenomeX Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 12,103 PhenomeX Inc. Common Stock shares in Q3 2021, an estimated $542K.
  • Raymond James & Associates first reported a position in PhenomeX Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Raymond James & Associates's PhenomeX Inc. Common Stock position peaked at $777K in Q4 2020.
  • 137 funds tracked by Wall St. Rank held PhenomeX Inc. Common Stock as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.